Autism – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Autism – Pipeline Review, H1 2017’, provides an overview of the Autism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Autism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Autism and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Autism

The report reviews pipeline therapeutics for Autism by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Autism therapeutics and enlists all their major and minor projects

The report assesses Autism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Autism

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Autism

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Addex Therapeutics Ltd

Aequus Pharmaceuticals Inc

AgeneBio Inc

Anima Biotech Ltd

APeT Holding BV

Avanir Pharmaceuticals Inc

BioCrea GmbH

BioHealthonomics Inc

BrainStorm Cell Therapeutics Inc

Confluence Pharmaceuticals LLC

Coronis NeuroSciences Ltd

Curemark LLC

DRI Biosciences Corp

F. Hoffmann-La Roche Ltd

GW Pharmaceuticals Plc

Heptares Therapeutics Ltd

Immuron Ltd

Intra-Cellular Therapies Inc

Leading BioSciences Inc

MedDay SA

Omeros Corp

OptiNose US Inc

Sumitomo Chemical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Autism - Overview

Autism - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Autism - Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

Aequus Pharmaceuticals Inc

AgeneBio Inc

Anima Biotech Ltd

APeT Holding BV

Avanir Pharmaceuticals Inc

BioCrea GmbH

BioHealthonomics Inc

BrainStorm Cell Therapeutics Inc

Confluence Pharmaceuticals LLC

Coronis NeuroSciences Ltd

Curemark LLC

DRI Biosciences Corp

F. Hoffmann-La Roche Ltd

GW Pharmaceuticals Plc

Heptares Therapeutics Ltd

Immuron Ltd

Intra-Cellular Therapies Inc

Leading BioSciences Inc

MedDay SA

Omeros Corp

OptiNose US Inc

Sumitomo Chemical Co Ltd

Autism - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Autism - Drug Profiles

(dextromethorphan + quinidine sulfate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

acamprosate calcium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ACT-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADX-71441 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADX-88178 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aripiprazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CB-0306 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CM-AT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CP-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Autism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GWP-42006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

histamine dihydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HTL-14242 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMM-124E - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

L-179 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lumateperone tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lurasidone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MD-1103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

niacinamide CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NurOwn - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxytocin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAM-28 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Insulin Like Growth Factor 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-7314 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SF-999 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GABRA5 Receptor for CNS Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Block Chloride Channels for Autism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target GPR63 for Autism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target Oxytocin for Autism and Anxiety Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Autism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Translation Initiation Factor-4E for Autism and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Autism - Dormant Projects

Autism - Discontinued Products

Autism - Product Development Milestones

Featured News & Press Releases

Sep 22, 2016: Blum Study - A Phase 3 Clinical Trial for Children with Autism

Jul 20, 2016: Immuron to Cooperate with Leading Australian Universities on Autism Research

Feb 04, 2016: Aequus Announces Positive Results from Single-Dose Bioavailability Study of Aripiprazole Transdermal Patch

Jul 23, 2015: Positive Preclinical Results and Patent Allowed for Aequus' Once-Weekly Transdermal Aripiprazole

May 11, 2015: Curemark Launches New Phase III Trial in Expanded Population of Children with Autism

Nov 04, 2013: Curemark Begins NDA Submission for CM-AT Autism Treatment

Sep 06, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt

Sep 03, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis

Aug 14, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz

Apr 23, 2013: Curemark Announces Positive Pre-NDA Meeting With FDA For New Drug Application For CM-AT For Autism

Aug 15, 2012: Omeros Unlocks Over Half Of Class A Orphan G Protein-Coupled Receptors

Aug 06, 2012: Curemark To Enroll Children 9-12 Years Of Age Into Medical Trial Of CM-AT For Children With Autism

May 31, 2012: Study Reports New Treatment For Irritability In Autism

Dec 07, 2011: Curemark Reports Positive Phase III Results Of CM-AT In Children With Autism

Mar 21, 2011: Curemark Completes Enrollment Of Phase III Trials For CM-AT In Autism

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Autism, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Autism – Pipeline by Addex Therapeutics Ltd, H1 2017

Autism – Pipeline by Aequus Pharmaceuticals Inc, H1 2017

Autism – Pipeline by AgeneBio Inc, H1 2017

Autism – Pipeline by Anima Biotech Ltd, H1 2017

Autism – Pipeline by APeT Holding BV, H1 2017

Autism – Pipeline by Avanir Pharmaceuticals Inc, H1 2017

Autism – Pipeline by BioCrea GmbH, H1 2017

Autism – Pipeline by BioHealthonomics Inc, H1 2017

Autism – Pipeline by BrainStorm Cell Therapeutics Inc, H1 2017

Autism – Pipeline by Confluence Pharmaceuticals LLC, H1 2017

Autism – Pipeline by Coronis NeuroSciences Ltd, H1 2017

Autism – Pipeline by Curemark LLC, H1 2017

Autism – Pipeline by DRI Biosciences Corp, H1 2017

Autism – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Autism – Pipeline by GW Pharmaceuticals Plc, H1 2017

Autism – Pipeline by Heptares Therapeutics Ltd, H1 2017

Autism – Pipeline by Immuron Ltd, H1 2017

Autism – Pipeline by Intra-Cellular Therapies Inc, H1 2017

Autism – Pipeline by Leading BioSciences Inc, H1 2017

Autism – Pipeline by MedDay SA, H1 2017

Autism – Pipeline by Omeros Corp, H1 2017

Autism – Pipeline by OptiNose US Inc, H1 2017

Autism – Pipeline by Sumitomo Chemical Co Ltd, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Autism – Dormant Projects, H1 2017

Autism – Dormant Projects, H1 2017 (Contd..1), H1 2017

Autism – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Autism, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports